FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By...

FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; O

BenzingaJul 3 01:36

Cassava Forms Committee After US Probe, Researcher Fraud

Yahoo FinanceJul 2 03:54

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.

BenzingaJul 2 01:35

Why Cassava Sciences Stock Is Sinking Today

Yahoo FinanceJul 2 00:19

Cassava Sciences Down Another 3% as SEC Provides Update on Simufilam Probe

Seeking AlphaJul 2 00:17

Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation

Cassava Sciences (NASDAQ:SAVA) has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employ

BenzingaJul 1 23:19